BridgeMD
New treatment option for ADHD - Attention Deficit Disorder With Hyperactivity
Official title ADRIS Driving Simulator for Adolescents With Attention Deficit and Hyperactivity Disorder
ClinicalTrials.gov ID: NCT07478458
What this study is testing
- What it's testing
- This study aims to evaluate a new driving simulator, called ADRIS 2.1, developed for adolescents aged 13-18 years with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common neurodevelopmental disorder that can affect attention, self-control, and decision-making.
- Time commitment: about 6 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 13 to 18. Healthy volunteers may be eligible.
You may be able to join if
- for ADHD people:
- Age range 13-18 years (up to the age of nineteen)
- Diagnosis of ADHD (hyperactive, inattentive and combined subtype)
- Consent to participate in the study by the participant or, in the case of a minor, by their parent(s)/guardian(s). for Control Group people:
- Age- and sex-matched neurotypical adolescents
You likely can't join if
- Visual deficits not corrected/correctable with the normal use of lenses.
- Motor deficits clinically detected and/or previously diagnosed and that could compromise the use of the simulator (e.g. neurological diseases...
- Categorical diagnoses according to DSM-5 criteria such as Psychosis, Mood Disorders, Autism Spectrum Disorders, Intellectual Disabilities, Borderline...
- Patients with other conditions that could affect driving ability.
- Denial / withddrawal of consent to the protocol
See the full eligibility criteria
- for ADHD people:
- Age range 13-18 years (up to the age of nineteen)
- Diagnosis of ADHD (hyperactive, inattentive and combined subtype)
- Consent to participate in the study by the participant or, in the case of a minor, by their parent(s)/guardian(s). for Control Group people:
- Age- and sex-matched neurotypical adolescents
- No diagnosis of ADHD or other neurodevelopmental disorders
- Informed consent obtained from the participant if of legal age or from the legal guardian and assent from the minor
- Visual deficits not corrected/correctable with the normal use of lenses.
- Motor deficits clinically detected and/or previously diagnosed and that could compromise the use of the simulator (e.g. neurological diseases, psychiatric diseases, etc.).
- Categorical diagnoses according to DSM-5 criteria such as Psychosis, Mood Disorders, Autism Spectrum Disorders, Intellectual Disabilities, Borderline Intellectual Functioning, Anxiety Disorders.
- Patients with other conditions that could affect driving ability.
- Denial / withddrawal of consent to the protocol
The study team makes the final eligibility decision.
Where it's taking place
- Genoa, GE, Italy
- Pisa, PI, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 13 years to 18 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Genoa, GE, Italy; Pisa, PI, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.